Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 0.51 |
| ▸ | CTSG | P08311 | 4/20 | 0.37 |
| ▸ | CMA1 | P23946 | 3/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837054 | 1.00 | FGFR4 (0.51) | FGFR4CTSGCMA1TNK2MAP4K2 | |
| SCHEMBL6617528 | 0.87 | FGFR4 (0.44) | FGFR4TNK2MAP4K2ABL1PDGFRB | |
| SCHEMBL6622724 | 0.85 | TNK2 (0.43) | FGFR4TNK2MAP4K2EGFRABL1 | |
| SCHEMBL6623008 | 0.84 | FGFR4 (0.43) | FGFR4EGFR | |
| SCHEMBL6070019 | 0.84 | FGFR4 (0.40) | FGFR4TNK2MAP4K2ABL1PDGFRB | |
| SCHEMBL15413275 | 0.84 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL6619527 | 0.83 | FGFR4 (0.40) | FGFR4TNK2MAP4K2ABL1PDGFRB | |
| SCHEMBL5231241 | 0.82 | FGFR4 (0.52) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL6622591 | 0.82 | FGFR4 (0.40) | FGFR4TNK2MAP4K2ABL1PDGFRB | |
| SCHEMBL6619503 | 0.82 | FGFR4 (0.46) | FGFR4TNK2MAP4K2EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| EP-1123295-B1 | BICYCLIC NITROGEN HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2004-09-29 | — | — | EP | disclosed |
| EP-1123295-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| US-6150373-A | AMINO-SUBSTITUTED DIHYDROPYRIMIDO(4,5-D)PYRIMIDINONE DERIVATIVES; INHIBITORS OF THE T-CELL TYROSINE KINASE P56LCK; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY/-CARCINOGENIC AGENTS; BRONCHOPULMONARY, DERMATOLOGICAL AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR4 40/4885CTSG 2613/4885CMA1 1855/4885 |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR4 40/4885CTSG 2613/4885CMA1 1855/4885 |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | FGFR4 40/4885CTSG 2613/4885CMA1 1855/4885 |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | FGFR4 40/4885CTSG 2613/4885CMA1 1855/4885 |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR4 40/4885CTSG 2613/4885CMA1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.